Clementia Pharmaceuticals
Developer of a drug to treat fibrodysplasia ossificans progressiva.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
* | $1.3b Valuation: $1.3b | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2018 |
|---|---|
| Revenues | 0000 |
| EBITDA | 0000 |
| Profit | 0000 |
| EV | 0000 |
| EV / revenue | 00.0x |
| EV / EBITDA | 00.0x |
| R&D budget | 0000 |
Source: Company filings or news article
Related Content
Clementia Pharmaceuticals, a subsidiary of Ipsen, operates as a global biopharmaceutical company with a strong focus on developing innovative treatments for oncology, neuroscience, and rare diseases. The company aims to launch at least one new drug or meaningful indication each year, demonstrating a commitment to continuous innovation and patient care. Clementia serves a diverse range of clients, including healthcare providers, patients, and research institutions, primarily in the pharmaceutical and biotechnology markets. The business model revolves around research and development, clinical trials, and commercialization of new therapies. Revenue is generated through the sale of these therapies, partnerships, and collaborations with other pharmaceutical companies. The company leverages its biotech mindset and robust development and commercialization teams to maintain a competitive edge in the market.
Keywords: biopharmaceutical, oncology, neuroscience, rare diseases, innovation, clinical trials, commercialization, patient care, research, development.